IOL receives Korean FDA approval

The company’s pharmaceutical API products Ibuprofen and fenofibrate got the go-ahead

IOL Chemicals & Pharmaceuticals Ltd has received approval from the Korean Ministry of Food and Drug Safety (Korean FDA) for the company's pharmaceuticals API products 'IBUPROFEN and 'FENOFIBRATE'. The approval of the Korean FDA re-establishes the company's efforts to keep the highest quality standards and to increase its presence in the regulated markets. This will strengthen the company's presence in the South Korean market.

IOL Chemicals and Pharmaceuticals Limited is an innovation-driven bulk drug, intermediates and speciality chemicals company, built on a prolific history of progress and expansion over three decades. The company has strategically expanded its product portfolio with a pipeline of new products that will form a strong foundation for future growth